395 related articles for article (PubMed ID: 29668922)
1. Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.
Schönauen K; Le N; von Arnim U; Schulz C; Malfertheiner P; Link A
Inflamm Bowel Dis; 2018 Jun; 24(7):1547-1557. PubMed ID: 29668922
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
4. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
6. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
8. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
9. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
[TBL] [Abstract][Full Text] [Related]
11. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease.
Thorsvik S; Damås JK; Granlund AV; Flo TH; Bergh K; Østvik AE; Sandvik AK
J Gastroenterol Hepatol; 2017 Jan; 32(1):128-135. PubMed ID: 27640344
[TBL] [Abstract][Full Text] [Related]
12. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
13. Identification of microRNA-16-5p and microRNA-21-5p in feces as potential noninvasive biomarkers for inflammatory bowel disease.
Zhou R; Qiu P; Wang H; Yang H; Yang X; Ye M; Wang F; Zhao Q
Aging (Albany NY); 2021 Feb; 13(3):4634-4646. PubMed ID: 33535181
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.
Chen P; Li Y; Li L; Yu Q; Chao K; Zhou G; Qiu Y; Feng R; Huang S; He Y; Chen B; Chen M; Zeng Z; Zhang S
Aliment Pharmacol Ther; 2019 Mar; 49(6):733-743. PubMed ID: 30734320
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.
Schaefer JS; Attumi T; Opekun AR; Abraham B; Hou J; Shelby H; Graham DY; Streckfus C; Klein JR
BMC Immunol; 2015 Feb; 16():5. PubMed ID: 25886994
[TBL] [Abstract][Full Text] [Related]
16. [Significance of serum calprotectin in assessing inflammatory bowel disease activity].
Mao JY; Li L; Pang Z
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):3001-3004. PubMed ID: 29061007
[No Abstract] [Full Text] [Related]
17. Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn's disease: Correlations with disease activity, extent, and location.
Abdelazim SA; Shaker OG; Ali O; El-Tawil M; Senousy MA
Pathol Res Pract; 2023 Dec; 252():154910. PubMed ID: 37939427
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
19. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
20. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
